非布司他治疗痛风伴高尿酸血症患者的有效性及安全性研究

Effect and Safety Research of Febuxostat in Treatment of Gout with Hyperuricemia

目的研究分析非布司他治疗痛风伴高尿酸血症患者的有效性及安全性,为后续临床应用提供参考。方法以2017年8月-2019年12月广州泰康粤园医院收治的65例痛风伴高尿酸血症患者为研究对象,按照收治时间先后分为对照组及研究组,对照组采取常规性治疗,研究组加入非布司他治疗,对比两组的临床治疗效果、不同时间段的血尿酸水平、治疗前后IL-β、NALP3、不良反应。结果对照组及研究组的临床治疗总有效率分别为81.3%及96.9%;研究组治疗2个月、4个月、6个月后血尿酸水平均低于对照组(P<0.05);治疗后研究组的治疗前后IL-β、NALP3优于对照组(P<0.05);对照组及研究组的不良反应发生率分别为9.4%及12.1%,数据差异无统计学意义(P>0.05);治疗后研究组患者的肝肾功能优于对照组,数据差异具有统计学意义(P<0.05)。结论痛风伴高尿酸血症临床治疗方案中采取非布司他可获得理想效果,且安全性高,值得推荐使用。

Objective To study effect and safety of febuxostat in treatment of gout with hyperuricemia,and provide reference for follow-up clinical application.Methods The paper chose 65 patients with gout and hyperuricemia admitted to Guangzhou Taikang Yueyuan Hospital from August 2017 to December 2019,and divided them into control group and study group according to time of admission.Control group was treated with routine treatment,and study group with febuxostat.Clinical treatment effect,blood uric acid level in different time periods,IL-β,NALP3,adverse reactions before and after treatment was compared between two groups.Results Total effective rates of control group and study group was 81.3%and 96.9%respectively;serum uric acid level in study group was lower than control group after 2,4 and 6 months of treatment(P<0.05);IL-β,NALP3 before and after treatment in study group was higher than control group(P<0.05);incidence of adverse reactions in control group and study group was 9.4%and 12.1%respectively,with no statistical difference(P>0.05).After treatment,liver and kidney function of study group was better than control group,difference was statistically significant(P<0.05).Conclusion During clinical treatment of gout with hyperuricemia,febuxostat can obtain ideal effect with high safety,which is worth recommending.